Predictors of recurrence free survival for patients with stage II and III colon cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tsikitis, Vassiliki L ^a,b   Larson, David W ^b   Huebner, Marianne ^b   Lohse, Christine M ^b   Thompson, Patricia A ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Clinico pathologic; Disease free survival; Early stage colon cancer; Predictors of recurrence

Indexed keywords

FLUOROURACIL;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; COLON CANCER; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; PERINEURAL INVASION; PREDICTION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; COLON RESECTION; COLONIC NEOPLASMS; DISEASE COURSE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLECTOMY; COLONIC NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901347797     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-336     Document Type: Article

References (17)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, De Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351. 10.1056/NEJMoa032709, 15175436.
3. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029. 10.1016/S0140-6736(07)61866-2, 18083404.
4. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology:colon cancer. J Natl Compr Canc Netw 2009, 7:778-831.
5. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4, 8668867.
6. Harris GJ, Church JM, Senagore AJ, Lavery IC, Hull TL, Strong SA, Fazio VW. Factors affecting local recurrence of colonic adenocarcinoma. Dis Colon Rectum 2002, 45:1029-1034. 10.1007/s10350-004-6355-1, 12195186.
7. Colon and Rectum. AJCC Cancer Staging Manual 2010, 143-164. New York: Springer-Verlag, Edge SB, Compton CC, Fritz AG, Greene FL, Trotti AIII, 7.
8. Jeong SY, Chessin DB, Schrag D, Riedel E, Wong WD, Guillem JG. Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2005, 97:1705-1706. author reply 1706-7, 10.1093/jnci/dji383, 16288127.
9. Elferink MA, Visser O, Wiggers T, Otter R, Tollenaar RA, Langendijk JA, Siesling S. Prognostic factors for locoregional recurrences in colon cancer. Ann Surg Oncol 2012, 19:2203-2211. 10.1245/s10434-011-2183-4, 22219065.
10. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003, 21:2912-2919. 10.1200/JCO.2003.05.062, 12885809.
11. Ratto C, Sofo L, Ippoliti M, Merico M, Bossola M, Vecchio FM, Doglietto GB, Crucitti F. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum 1999, 42:143-154. discussion 154-8, 10.1007/BF02237119, 10211489.
12. Smalley SR, Benedetti JK, Williamson SK, Robertson JM, Estes NC, Maher T, Fisher B, Rich TA, Martenson JA, Kugler JW, Benson AB, Haller DG, Mayer RJ, Atkins JN, Cripps C, Pedersen J, Periman PO, Tanaka MS, Leichman CG, Macdonald J. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006, 24:3542-3547. 10.1200/JCO.2005.04.9544, 16877719.
13. Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Salz LB, Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 2008, 26:380-385. 10.1200/JCO.2007.14.1291, 18202413.
14. Scheer A, Auer RA. Surveillance after curative resection of colorectal cancer. Clin Colon Rectal Surg 2009, 22:242-250. 10.1055/s-0029-1242464, 2796101, 21037815.
15. Benson AB, Desch CE, Flynn PJ, Krause C, Loprinzi CL, Minski BD, Petrelli NJ, Pfister DG, Smith TJ, Somerfield MR. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 2000, 18:3586-3588.
16. Muller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau H, Hahn SA, Schmoll SH, Porschen R, Schmeigel W, Graeven U. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis 2008, 23:1033-1039. 10.1007/s00384-008-0504-2, 18594845.
17. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:609-618.